We are live on ! Find out more
ABBV icon

AbbVie

1,605 hedge funds and large institutions have $61.7B invested in AbbVie in 2015 Q3 according to their latest regulatory filings, with 77 funds opening new positions, 623 increasing their positions, 680 reducing their positions, and 110 closing their positions.

New
Increased
Maintained
Reduced
Closed

32% more call options, than puts

Call options by funds: $1.2B | Put options by funds: $907M

8% less repeat investments, than reductions

Existing positions increased: 623 | Existing positions reduced: 680

3% less funds holding

Funds holding: 1,6531,605 (-48)

6.53% less ownership

Funds ownership: 75.37%68.84% (-6.5%)

23% less capital invested

Capital invested by funds: $80.2B → $61.7B (-$18.5B)

30% less first-time investments, than exits

New positions opened: 77 | Existing positions closed: 110

38% less funds holding in top 10

Funds holding in top 10: 14288 (-54)

Holders
1,605
Holders Change
-48
Holders Change %
-2.9%
% of All Funds
44.79%
Holding in Top 10
88
Holding in Top 10 Change
-54
Holding in Top 10 Change %
-38.03%
% of All Funds
2.46%
New
77
Increased
623
Reduced
680
Closed
110
Calls
$1.2B
Puts
$907M
Net Calls
+$292M
Net Calls Change
+$17.6M
Name Holding Trade Value Shares
Change
Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$428M -$76.2M -1,170,667 -13%
BIM
27
BlackRock Investment Management
Delaware
$411M -$130M -1,996,880 -21%
EIP
28
Epoch Investment Partners
New York
$410M -$12.8M -197,296 -3%
Legal & General Group
29
Legal & General Group
United Kingdom
$400M +$12.9M +197,847 +3%
UBS Group
30
UBS Group
Switzerland
$388M +$10.8M +165,968 +2%
UBS AM
31
UBS AM
Illinois
$384M -$52.8M -811,601 -10%
O
32
OrbiMed
New York
$378M +$18.1M +278,200 +4%
Deutsche Bank
33
Deutsche Bank
Germany
$355M +$43.8M +672,937 +12%
CS
34
Credit Suisse
Switzerland
$327M -$23.9M -367,573 -6%
Goldman Sachs
35
Goldman Sachs
New York
$321M -$52.9M -812,905 -12%
EVM
36
Eaton Vance Management
Massachusetts
$318M +$149M +2,289,013 +64%
BlackRock
37
BlackRock
New York
$314M -$10.3M -157,513 -3%
Franklin Resources
38
Franklin Resources
California
$298M +$8.48M +130,329 +2%
WIM
39
Woodford Investment Management
United Kingdom
$287M +$344M +5,277,800 New
PNC Financial Services Group
40
PNC Financial Services Group
Pennsylvania
$278M +$9.9M +152,117 +3%
Charles Schwab
41
Charles Schwab
California
$272M -$11.6M -178,769 -3%
AllianceBernstein
42
AllianceBernstein
Tennessee
$268M +$16.4M +251,424 +5%
Sumitomo Mitsui Trust Group
43
Sumitomo Mitsui Trust Group
Japan
$258M +$10.2M +157,387 +3%
New York State Common Retirement Fund
44
New York State Common Retirement Fund
New York
$253M +$5.95M +91,385 +2%
Fayez Sarofim & Co
45
Fayez Sarofim & Co
Texas
$246M -$13.7M -210,542 -4%
Ameriprise
46
Ameriprise
Minnesota
$240M -$189M -2,896,052 -40%
California Public Employees Retirement System
47
California Public Employees Retirement System
California
$239M -$7.49M -115,100 -3%
Boston Partners
48
Boston Partners
Massachusetts
$239M -$6M -92,250 -2%
Royal Bank of Canada
49
Royal Bank of Canada
Ontario, Canada
$236M -$4.51M -69,322 -2%
AIM
50
abrdn Investment Management
United Kingdom
$226M -$6.66M -102,340 -2%

ABBV Hedge Fund Activity: Q3 2015 in Review

1,605 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q3 2015, worth a combined $61.7B — down 23% from $80.2B a quarter earlier.

Sellers outnumbered buyers: 110 funds closed out of ABBV and 77 opened new positions — a net loss of 33 holders — while 680 trimmed existing stakes and 623 added.

The largest buyer was Bank of America, adding an estimated $549M. The largest seller was Morgan Stanley, cutting an estimated $1.44B.

  • 1,605 institutional investors held AbbVie (ABBV) as of Q3 2015, down from 1,653 in Q2 2015.
  • Funds reported $61.7B of AbbVie stock for Q3 2015, down 23% quarter-over-quarter.
  • 77 funds opened new AbbVie positions in Q3 2015 and 110 closed out, a net change of -33 holders.
  • The largest AbbVie buyer in Q3 2015 was Bank of America, an estimated $549M added.
  • The largest AbbVie seller in Q3 2015 was Morgan Stanley, an estimated $1.44B sold.

Based on aggregated 13F filings for Q3 2015.